Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Drop in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) saw a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 104,299 shares, a decline of 22.4% from the January 29th total of 134,358 shares. Based on an average trading volume of 2,250,315 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.4% of the shares of the company are sold short. Currently, 1.4% of the shares of the company are sold short. Based on an average trading volume of 2,250,315 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ernexa Therapeutics has an average rating of “Sell”.

Ernexa Therapeutics Price Performance

ERNA opened at $0.29 on Monday. The company’s 50 day simple moving average is $0.91 and its 200-day simple moving average is $1.20. Ernexa Therapeutics has a one year low of $0.27 and a one year high of $4.50. The stock has a market capitalization of $2.27 million, a P/E ratio of -0.10 and a beta of 6.58.

Institutional Investors Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is currently owned by institutional investors and hedge funds.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.